ONTX News and Press, Onconova Therapeutics Inc. From 08/11/22

NEWTOWN, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three m...

Onconova Therapeutics ( NASDAQ: ONTX ) is scheduled to announce Q2 earnings results on Thursday, August 11th, after market close. The consensus EPS Estimate is -$0.20 (+25.9% Y/Y) and the consensus Revenue Estimate is $0.06M (flat Y/Y). Over the last 1 year, ONTX has...

NEWTOWN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to relea...

Onconova Therapeutics (NASDAQ:ONTX) appoints Mark Guerin as the COO in addition to his current role as company’s CFO. Mr. Guerin has worked in numerous roles at the company since he joined in September 2013 following its IPO in July 2013 and has served as company’...

Mark Guerin promoted to Chief Operating Officer and Chief Financial Officer Dr. Adar Makovski Silverstein promoted to Senior Director and Head of Corporate Development NEWTOWN, Pa., June 13, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-st...

NEWTOWN, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of an abstract at the American Society of Clin...

If you’re shopping for a wallet and one comes complete with $100 worth of cash inside, and is priced at $60, would you think there is value to this purchase? A situation similar to this has evolved in many biotech stocks. Their balance sheet cash and cash equivalents exceed their market...

Onconova Reported 1Q22. Onconova reported a loss of $4.1 million or $(0.20) per share and gave updates to its clinical trial progress. The Phase 1 dose escalation trials for narazaciclib in solid organ tumors continue to treat patients. The trial in China continues to treat its fifth cohort, w...

Onconova Therapeutics, Inc. (ONTX) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Avi Oler - Senior Vice President-Corporate Development and General Counsel Steve Fruchtman - President and Chief Executive Officer Mark Gelder - Chief Medical Officer Mark Guerin -...

Onconova Therapuetics (NASDAQ:ONTX) saw its Q1 2022 net loss narrow ~13% year-over-year to ~4.1M (-$0.20 per share, basic and diluted) even as revenue was unchanged. Revenue in the quarter was $56K. The cancer therapy company missed on the top and bottom lines. Operating expenses were also fl...